Navigation Links
Diatos Announces Positive Clinical Results for its DTS-201,Doxorubicin Prodrug Program

the tumor site, avoiding systemic side effects. DTS-301 is in Phase II clinical studies and was in-licensed from Protherics PLC (LSE: PTI / NASDAQ: PTIL).

-- DTS-201, a doxorubicin prodrug, increases the concentration of doxorubicin, a widely used cancer drug, at the tumor site by means of a reactivation mechanism specific to the tumor environment. DTS-201 has completed Phase I clinical studies in Belgium and France in Q2-07. Exclusive European rights for DTS-201 were in-licensed from Medarex Inc.

-- DTS-108 is a prodrug of SN-38, the active metabolite of the widely-used cancer drug irinotecan, and is based on Diatos' Vectocell(R) technology. DTS-108 aims to increase the efficacy of SN-38 while reducing the toxic effects of irinotecan. DTS-108 is in preclinical development.

For more information on Diatos, please visit www.diatos.com.

The Diatos logo and Vectocell(R) are registered trademarks of Diatos SA.

Contact

Diatos SA
General enquiries
Dr John Tchelingerian, PhD, President & CEO
c/o Virginie Leplat
Director of Human Resources & Administration
Tel.: +33 (0)1 53 80 93 80
vleplat@diatos.com
or
c/o Guillaume Dussert, Associate BD & Marketing Manager
Tel.: +33-(0)1 53 80 93 83
gdussert@diatos.com
or
Medical enquiries
Dr Jamal Gasmi, MD, MSc
Chief Medical Officer
Head of Clinical Development & Regulatory Affairs
Tel.: +33 (0)1 53 80 93 53
jgasmi@diatos.com
or
Press contacts
Northbank Communications
Justine Lamond, +44 (0)20 7268 3242





Page: 1 2 3 4 5

Related medicine technology :

1. Antisoma Announces Further Data From ASA404 Ovarian Cancer Trial
2. Neose Announces Presentation of Positive Preclinical Data on GlycoPEGylated Factor VIIa at the XXI Congress of the International Society on Thrombosis and Haemostasis
3. Biofrontera AG Announces Clinical Study Confirms Excellent Efficacy of BF-200 ALA In Actinic Keratosis
4. YM BioSciences Announces Secondary Efficacy and Safety Findings in Randomized Phase IIB Aerolef Trial
5. BioSante Pharmaceuticals Announces New Findings for Potential Bird Flu Vaccine
6. Portola Pharmaceuticals Announces Positive Data from a Phase II Study of its Factor Xa Inhibitor at the XXI Congress of the International Society on Thrombosis and Haemostasis
7. Manhattan Pharmaceuticals Announces Results of Phase 2a Studies for Oral Oleoyl-estrone
8. AVI BioPharma Partner Cook Medical Announces Completion of Patient Enrollment for APPRAISAL Phase II Clinical Trial for Treatment of Cardiovascular Disease
9. Protox Announces Positive Clinical Data from Prostate Cancer Study
10. Inspire Announces Webcast of Presentation at C.E. Unterberg, Towbin Emerging Growth Opportunities Conference
11. NexMed Announces Completion of Patient Enrollment in Two Pivotal Phase 3 Studies for Anti-Fungal Product
Post Your Comments:
(Date:9/2/2015)... , Sept. 2, 2015  The report on breast ... of breast cancer drugs on the basis of the ... originates from the inner lining of milk ducts or ... malignant type of tumor that can spread to other ... which starts in lobules is referred as lobular carcinoma, ...
(Date:9/2/2015)... LONDON , Sept. 2, 2015 ... coil is used to treat an unruptured and ... artery wall). The treatment is either known as ... procedure, the endovascular coil blocks the blood flow ... usually performed under general anaesthesia by an interventional ...
(Date:9/2/2015)...  Array BioPharma Inc. (Nasdaq: ARRY ) ... Ron Squarer , will present at the Wells ... is welcome to participate in the conference through ... Fargo Securities Healthcare ConferencePresenter: Ron Squarer, Chief Executive ... a.m. Eastern Time Webcast: www.arraybiopharma.com   ...
Breaking Medicine Technology:Breast Cancer Therapeutics: Pipeline Analysis Market - Global Industry Analysis, Size, Share, Growth, Trends and Forecast 2015 - 2023 2Breast Cancer Therapeutics: Pipeline Analysis Market - Global Industry Analysis, Size, Share, Growth, Trends and Forecast 2015 - 2023 3Global Neuroendovascular Coil Market 2015-2019 2
... LOS ANGELES, Oct. 24, 2011 NeuroSigma, Inc., a ... has signed a contract with the University of California, ... clinical trial to study the use of non-invasive, external ... Deficit Hyperactivity Disorder (ADHD).  NeuroSigma is the exclusive worldwide ...
... HealthWarehouse.com, Inc. (OTC: HEWA), a leading VIPPS-accredited ... begin providing prescription medications for WhiteGlove Health, Inc., ... excited to have a national partner to provide ... Robert Fabbio, co-founder and chief executive officer of ...
Cached Medicine Technology:NeuroSigma Funds First-Ever Pediatric Clinical Trial to Study Non-Invasive External Trigeminal Nerve Stimulation for the Treatment of ADHD 2NeuroSigma Funds First-Ever Pediatric Clinical Trial to Study Non-Invasive External Trigeminal Nerve Stimulation for the Treatment of ADHD 3WhiteGlove Health Selects HealthWarehouse.com to Provide Prescription Medications to its Members Nationwide 2
(Date:9/2/2015)... ... September 02, 2015 , ... Alameda County Community Food ... Action Month” during the entire month of September. In the spirit of ... its efforts this September to an awareness campaign educating legislators and the public ...
(Date:9/2/2015)... (PRWEB) , ... September 02, 2015 , ... ... Cancer Center at Children's Healthcare of Atlanta to help support childhood cancer ... discuss the upcoming WSB Radio Care-A-Thon , which is the fund-raising event ...
(Date:9/2/2015)... ... September 02, 2015 , ... Medical ... has completed a recapitalization with new investment partners Beecken Petty O’Keefe & ... each offer extensive expertise and connections within the healthcare industry, which makes ...
(Date:9/2/2015)... (PRWEB) , ... September 02, 2015 , ... Every year ... it; others dread it. However, few are prepared to face the academic workload confronting ... starts. Our schools haven’t prepared them since schools don’t teach students how to study. ...
(Date:9/2/2015)... Destin, Florida (PRWEB) , ... September 02, 2015 , ... ... in drug prices over the past year and its negative impact on consumers. It ... regular prescription medication and 10% were paying as much as an extra $100 compared ...
Breaking Medicine News(10 mins):Health News:#IfOnlyYouKnew: Alameda County Community Food Bank Commemorates September as National Hunger Action Month 2Health News:#IfOnlyYouKnew: Alameda County Community Food Bank Commemorates September as National Hunger Action Month 3Health News:#IfOnlyYouKnew: Alameda County Community Food Bank Commemorates September as National Hunger Action Month 4Health News:DoMyOwnPestControl.com Goes Gold for Childhood Cancer Awareness Month 2Health News:Medical Solutions Completes Recapitalization with Beecken Petty O’Keefe & Company and Heritage Group 2Health News:Medical Solutions Completes Recapitalization with Beecken Petty O’Keefe & Company and Heritage Group 3Health News:Medical Solutions Completes Recapitalization with Beecken Petty O’Keefe & Company and Heritage Group 4Health News:5 Essential Study Tips Every Student Needs for Academic Success but Schools Do Not Teach 2Health News:5 Essential Study Tips Every Student Needs for Academic Success but Schools Do Not Teach 3Health News:Watertree Health President Responds to Consumer Reports Survey on Rising Prescription Drug Prices 2
... says hazard isn,t proven, , SATURDAY, Sept. 5 (HealthDay ... (pronounced THAL ates) are nearly ubiquitous in consumer products, ... plastics and toys. , A little over a decade ... began to focus on phthalates and have been working ...
... , ST. LOUIS, Sept, 4 KV ... Thomas McHugh, the Vice President of Finance and Corporate Controller of ... Mr. McHugh replaces Ronald J. Kanterman, who ceased serving as ... Mr. Kanterman continues to serve as a member of the ...
... NEWPORT BEACH, Calif., Sept. 4 Nationwide Health Properties ... Portfolio Officer, Abdo Khoury, will participate on a healthcare real estate ... Conference on Friday, September 11, 2009 beginning at 7:30 a.m. CDT. ... a live audio-webcast, please us the following link: ...
... University of Toronto have identified a protein which plays ... could enhance our understanding of how the brain works, ... of T graduate student John Calarco, working in the ... and Biomolecular Research, University of Toronto) and Prof. Mei ...
... major episode later, researchers say , FRIDAY, Sept. 4 ... to have major depression, anxiety disorders and eating disorders ... researchers interviewed 755 teenagers who were about age 16 ... substance abuse. , About 8 percent were found to ...
... ... ... American Pharmacists Association (APhA) is recommending that the public begin visiting their ... 80,000 pharmacists have been trained to administer immunizations and have the authority to administer ...
Cached Medicine News:Health News:In Toys and More, Are Chemicals Safe or Harmful? 2Health News:In Toys and More, Are Chemicals Safe or Harmful? 3Health News:KV Pharmaceutical Appoints Interim Chief Financial Officer 2Health News:KV Pharmaceutical Appoints Interim Chief Financial Officer 3Health News:KV Pharmaceutical Appoints Interim Chief Financial Officer 4Health News:KV Pharmaceutical Appoints Interim Chief Financial Officer 5Health News:KV Pharmaceutical Appoints Interim Chief Financial Officer 6Health News:U of T researchers identify protein 2Health News:Depressed Teens Continue to Suffer 2Health News:Pharmacists Urge the Public to Begin Getting Immunized 2Health News:Pharmacists Urge the Public to Begin Getting Immunized 3
... System RCS 800 closes various plastic primary and ... way. Different tube heights and diameters can be ... be used for send-outs. The integration into other ... System RSD 800 and High Throughput Sorter RSD ...
... Decapping System DS 800 selectively removes closures from ... the barcode towards the rack opening in one ... integrated in PVT Systems like Sorting System RS ... Sorter RSD ProVolume and Aliquoting System RSD 800A. ...
... Nanogen offers reagents to detect ... human parainfluenza virus 1, 2 and ... and respiratory syncytial virus A and ... reagents to create homebrew tests., ...
... Alert Detection Reagents provide molecular labs a ... assays. By using our MGB technology, combined ... is now able to provide molecular labs ... sequences of specific organisms or genetic mutations ...
Medicine Products: